GermanyGermany

Stopping malaria at the membrane

08.07.2010

Hamburg – To survive in man, the malaria parasite Plasmodium falciparum needs to enter the red blood cells for reproduction. Researchers from the Bernhard ­Nocht Institute for Tropical Medicine in Hamburg have now identified the internal signal that triggers the invasion of human erythrocytes. “To enter the cell, the parasites first have to come into intimate contact with the blood cells,” says Tim Gillberger, who conducted the research (PLoS Pathog. 6(6):e1000941). “If we are able to block the molecular mechanism behind that process, the pathogen wouldn’t stand a chance of successful infection.“ Gillberger and colleagues have already started compound screening for so-called PfPKA inhibitors – compounds that block the enzyme cAMP dependent protein kinase A. As the researchers reported in mid-June, PfPKAs are required for the formation of so-called tight junctions between Plasmodium and the blood cell. The enzymes activate the parasite surface protein AMA1 by phosphorylation, which triggers formation of tight junction formation and thus blood cell invasion. Gilberger believes the discovery opens the path to the development of new malaria drugs and vaccines.



GermanyGermany

27.10.2011

Leverkusen - Bayer Pharma has a lucky streak. The pharma division of the German chemical giant announced positive Phase III results from regorafenib in colorectal cancer. “We are extremely encouraged by the result of this...

GermanyGermany

24.10.2011

Leverkusen - A short statement from the European Medicines Agency (EMA) and a big step for the German biotech Biofrontera. The agency issued a favourable opinion on Biofrontera's marketing approval application for its drug for...

GermanyGermany

14.10.2011

Leverkusen/San Francisco - Bayer HealthCare and Onyx Pharmaceuticals will not to court over Nevaxar. The two companies reached an agreement related to regorafenib, a late-stage oncology compound. Regorafenib is an oral...

GermanyGermany

11.10.2011

Ingelheim/Ridgefield –Boehringer Ingelheim’s COPD treatment Combivent Respimat has been approved by the U.S. Food and Drug Administration (FDA) for the US market. The new, propellant-free inhaler product for the beta adrenergic...

GermanyGermany

01.10.2011

Rostock – German researchers say overexpression of one of the 49 transport proteins that shuttle substances over the blood-brain barrier could be the key to treating Alzheimer’s disease. In mice, the group headed by Jens Pahnke...

GermanyGermany

27.09.2011

Rehovot/Monheim – Bayer Crop Science may be a step closer to introducing desirable traits in wheat. In the collaboration with Israeli Evogene Ltd. the German company has reached a milestone. Utilising Evogene‘s proprietary...

GermanyGermany

22.09.2011

Willich – Brasilian biopolymer producer Braskem and German bioplastics compounding specialist FKuR GmbH, have signed a compounding agreement for green polyethylene. The tailor-made product will be a first in Europe, according...

GermanyGermany

08.09.2011

Leverkusen - It was a black Tuesday for Bayer. After rumours were leaked out that the FDA has doubts over the German pharmaceutical company's potential blockbuster Xarelto, the shares temporarily dropped as much as 17 percent....

GermanyGermany

06.09.2011

Bad Homburg - German VC firm Creathor venture announced the first closing of its Creathor Venture Fund III. Now, the company is poised to mete out €51million of fresh capital to start-ups. Life science companies will be among the...

Displaying results 21 to 30 out of 454

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-germany/browse/2/article/stopping-malaria-at-the-membrane.html

Events

All Events

Stock list

All quotes

TOP

  • WILEX2.48 EUR3.77%
  • 4SC1.12 EUR2.75%
  • VITA 344.00 EUR2.04%

FLOP

  • ADDEX2.99 CHF-7.14%
  • BIOFRONTERA2.18 EUR-5.22%
  • SARTORIUS94.26 EUR-3.32%

TOP

  • SANTHERA92.00 CHF43.5%
  • CO.DON3.02 EUR26.9%
  • PAION2.98 EUR19.7%

FLOP

  • EVOTEC3.00 EUR-20.0%
  • ADDEX2.99 CHF-18.5%
  • 4SC1.12 EUR-15.8%

TOP

  • SANTHERA92.00 CHF2211.6%
  • CO.DON3.02 EUR247.1%
  • PAION2.98 EUR189.3%

FLOP

  • CYTOS0.24 CHF-94.0%
  • MERCK KGAA67.23 EUR-41.4%
  • THERAMETRICS0.09 CHF-40.0%

No liability assumed, Date: 16.09.2014


Current issue

All issues

Product of the week

Products